Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Management of pleural effusions in the neonate

Joseph B Philips III, MD, FAAP
Thomas Prescott Atkinson, MD, PhD
Section Editor
Leonard E Weisman, MD
Deputy Editor
Melanie S Kim, MD


Pleural effusion occurs as a result of an abnormal fluid collection within the pleural space. Once a pleural effusion has been diagnosed in the neonate, management decisions are based on the effusion's effect on the respiratory status of the patient, which is primarily based on the size of the effusion, and the cause and chronicity of the condition.

The management of neonatal pleural effusions will be reviewed here. The etiology, clinical manifestations, and evaluation of neonatal pleural effusions are discussed separately. (See "Etiology, clinical manifestations, diagnosis and evaluation of pleural effusions in the neonate".)


Symptomatic/large effusions — Most infants with large congenital pleural effusions are diagnosed by antenatal ultrasound. Affected fetuses often are also diagnosed with hydrops fetalis, as they have collection of fluids in other locations (eg, ascites, skin edema, or pericardial effusion) (see "Etiology, clinical manifestations, diagnosis and evaluation of pleural effusions in the neonate", section on 'Hydrops fetalis'). In severe cases, fetal thoracentesis may have been performed in an attempt to prevent pulmonary hypoplasia in fetuses during the second trimester, and prior to delivery to facilitate neonatal delivery, and if needed, resuscitation [1]. In fetuses with hydrops fetalis, ex utero intrapartum treatment (EXIT) has also been used to allow drainage of pleural fluid in the partially delivered and intubated fetus prior to clamping of the umbilical cord, which maintains the fetoplacental circulation [2-4]. (See "Nonimmune hydrops fetalis", section on 'Prognosis' and "Prenatal diagnosis and management of bronchopulmonary sequestration", section on 'Prenatal management' and "Prenatal diagnosis and management of bronchopulmonary sequestration", section on 'Delivery'.)

For fetuses that are diagnosed with large pleural effusions, the delivery should be planned for a tertiary center with staff capable of resuscitating and managing neonates with respiratory compromise. In the delivery room, the neonatal team should anticipate the needs of the most severely affected patient and be prepared to provide respiratory support that includes intubation, positive pressure ventilation, and removal of fluid by needle aspiration. (See 'Needle aspiration' below and "Postnatal care of hydrops fetalis", section on 'Initial resuscitation' and "Neonatal resuscitation in the delivery room".)

Occasionally, an infant will be born with pleural effusions that were undiagnosed in utero. Many of these infants will be hydropic, which should lead to a strong suspicion of a pleural effusion.

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Jul 03, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Cardwell MS. Aspiration of fetal pleural effusions or ascites may improve neonatal resuscitation. South Med J 1996; 89:177.
  2. Chang YL, Lien R, Wang CJ, et al. Congenital chylothorax in three siblings. Am J Obstet Gynecol 2005; 192:2065.
  3. Horvers M, Mooij CF, Antonius TA. Is octreotide treatment useful in patients with congenital chylothorax? Neonatology 2012; 101:225.
  4. Prontera W, Jaeggi ET, Pfizenmaier M, et al. Ex utero intrapartum treatment (EXIT) of severe fetal hydrothorax. Arch Dis Child Fetal Neonatal Ed 2002; 86:F58.
  5. Margau R, Amaral JG, Chait PG, Cohen J. Percutaneous thoracic drainage in neonates: catheter drainage versus treatment with aspiration alone. Radiology 2006; 241:223.
  6. Graham DD, McGahren ED, Tribble CG, et al. Use of video-assisted thoracic surgery in the treatment of chylothorax. Ann Thorac Surg 1994; 57:1507.
  7. Brissaud O, Desfrere L, Mohsen R, et al. Congenital idiopathic chylothorax in neonates: chemical pleurodesis with povidone-iodine (Betadine). Arch Dis Child Fetal Neonatal Ed 2003; 88:F531.
  8. Murki S, Faheemuddin M, Gaddam P. Congenital chylothorax--successful management with chemical pleurodesis. Indian J Pediatr 2010; 77:332.
  9. Mitanchez D, Walter-Nicolet E, Salomon R, et al. Congenital chylothorax: what is the best strategy? Arch Dis Child Fetal Neonatal Ed 2006; 91:F153.
  10. Scottoni F, Fusaro F, Conforti A, et al. Pleurodesis with povidone-iodine for refractory chylothorax in newborns: Personal experience and literature review. J Pediatr Surg 2015; 50:1722.
  11. Hoff DS, Gremmels DB, Hall KM, et al. Dosage and effectiveness of intrapleural doxycycline for pediatric postcardiotomy pleural effusions. Pharmacotherapy 2007; 27:995.
  12. Sarkar S, Hussain N, Herson V. Fibrin glue for persistent pneumothorax in neonates. J Perinatol 2003; 23:82.
  13. Mathur NB, Singh B, Kumar A, Aggarwal SK. Successful treatment of congenital chylothorax using fibrin glue. Indian J Pediatr 2009; 76:758.
  14. Rifai N, Sfeir R, Rakza T, et al. Successful management of severe chylothorax with argon plasma fulguration and fibrin glue in a premature infant. Eur J Pediatr Surg 2003; 13:324.
  15. Nguyen D, Tchervenkov CI. Successful management of postoperative chylothorax with fibrin glue in a premature neonate. Can J Surg 1994; 37:158.
  16. Stenzl W, Rigler B, Tscheliessnigg KH, et al. Treatment of postsurgical chylothorax with fibrin glue. Thorac Cardiovasc Surg 1983; 31:35.
  17. Cleveland K, Zook D, Harvey K, Woods RK. Massive chylothorax in small babies. J Pediatr Surg 2009; 44:546.
  18. Matsukuma E, Aoki Y, Sakai M, et al. Treatment with OK-432 for persistent congenital chylothorax in newborn infants resistant to octreotide. J Pediatr Surg 2009; 44:e37.
  19. Kamiyama M, Usui N, Tani G, et al. Postoperative chylothorax in congenital diaphragmatic hernia. Eur J Pediatr Surg 2010; 20:391.
  20. Vasu V, Ude C, Shah V, et al. Novel surgical technique for insertion of pleuroperitoneal shunts for bilateral chylous effusions in Ex preterm infant at term corrected age. Pediatr Pulmonol 2010; 45:840.
  21. Engum SA, Rescorla FJ, West KW, et al. The use of pleuroperitoneal shunts in the management of persistent chylothorax in infants. J Pediatr Surg 1999; 34:286.
  22. Rheuban KS, Kron IL, Carpenter MA, et al. Pleuroperitoneal shunts for refractory chylothorax after operation for congenital heart disease. Ann Thorac Surg 1992; 53:85.
  23. Biewer ES, Zürn C, Arnold R, et al. Chylothorax after surgery on congenital heart disease in newborns and infants -risk factors and efficacy of MCT-diet. J Cardiothorac Surg 2010; 5:127.
  24. Beghetti M, La Scala G, Belli D, et al. Etiology and management of pediatric chylothorax. J Pediatr 2000; 136:653.
  25. Chan SY, Lau W, Wong WH, et al. Chylothorax in children after congenital heart surgery. Ann Thorac Surg 2006; 82:1650.
  26. Starzl TE, Koep LJ, Weil R 3rd, et al. Thoracic duct drainage in organ transplantation: will it permit better immunosuppression? Transplant Proc 1979; 11:276.
  27. GOWANS JL. The recirculation of lymphocytes from blood to lymph in the rat. J Physiol 1959; 146:54.
  28. Bialkowski A, Poets CF, Franz AR, Erhebungseinheit für seltene pädiatrische Erkrankungen in Deutschland Study Group. Congenital chylothorax: a prospective nationwide epidemiological study in Germany. Arch Dis Child Fetal Neonatal Ed 2015; 100:F169.
  29. Church JT, Antunez AG, Dean A, et al. Evidence-based management of chylothorax in infants. J Pediatr Surg 2017; 52:907.
  30. Jolliff CR, Cost KM, Stivrins PC, et al. Reference intervals for serum IgG, IgA, IgM, C3, and C4 as determined by rate nephelometry. Clin Chem 1982; 28:126.
  31. Cannizzaro V, Frey B, Bernet-Buettiker V. The role of somatostatin in the treatment of persistent chylothorax in children. Eur J Cardiothorac Surg 2006; 30:49.
  32. Chan GM, Lechtenberg E. The use of fat-free human milk in infants with chylous pleural effusion. J Perinatol 2007; 27:434.
  33. Caserío S, Gallego C, Martin P, et al. Congenital chylothorax: from foetal life to adolescence. Acta Paediatr 2010; 99:1571.
  34. Fernández Alvarez JR, Kalache KD, Graŭel EL. Management of spontaneous congenital chylothorax: oral medium-chain triglycerides versus total parenteral nutrition. Am J Perinatol 1999; 16:415.
  35. Stajich GV, Ashworth L. Octreotide. Neonatal Netw 2006; 25:365.
  36. Das A, Shah PS. Octreotide for the treatment of chylothorax in neonates. Cochrane Database Syst Rev 2010; :CD006388.
  37. Shah D, Sinn JK. Octreotide as therapeutic option for congenital idiopathic chylothorax: a case series. Acta Paediatr 2012; 101:e151.
  38. Landis MW, Butler D, Lim FY, et al. Octreotide for chylous effusions in congenital diaphragmatic hernia. J Pediatr Surg 2013; 48:2226.
  39. Arevalo RP, Bullabh P, Krauss AN, et al. Octreotide-induced hypoxemia and pulmonary hypertension in premature neonates. J Pediatr Surg 2003; 38:251.
  40. Mohseni-Bod H, Macrae D, Slavik Z. Somatostatin analog (octreotide) in management of neonatal postoperative chylothorax: is it safe? Pediatr Crit Care Med 2004; 5:356.
  41. Reck-Burneo CA, Parekh A, Velcek FT. Is octreotide a risk factor in necrotizing enterocolitis? J Pediatr Surg 2008; 43:1209.
  42. Laje P, Halaby L, Adzick NS, Stanley CA. Necrotizing enterocolitis in neonates receiving octreotide for the management of congenital hyperinsulinism. Pediatr Diabetes 2010; 11:142.
  43. Radetti G, Gentili L, Paganini C, Messner H. Cholelithiasis in a newborn following treatment with the somatostatin analogue octreotide. Eur J Pediatr 2000; 159:550.
  44. Kugelman A, Gonen R, Bader D. Potential role of high-frequency ventilation in the treatment of severe congenital pleural effusion. Pediatr Pulmonol 2000; 29:404.
  45. Ragosta KG, Alfieris G. Chylothorax: a novel therapy. Crit Care Med 2000; 28:1208.
  46. Berkenbosch JW, Withington DE. Management of postoperative chylothorax with nitric oxide: a case report. Crit Care Med 1999; 27:1022.
  47. Sersar SI. Predictors of prolonged drainage of chylothorax after cardiac surgery: single centre study. Pediatr Surg Int 2011; 27:811.
  48. Thorlacius EM, Mellander M, Synnergren M, Kokinsky E. Late eosinophilic pleural effusion after cardiac surgery in a neonate--prompt response to corticosteroid therapy. Paediatr Anaesth 2009; 19:633.
  49. Malleske DT, Yoder BA. Congenital chylothorax treated with oral sildenafil: a case report and review of the literature. J Perinatol 2015; 35:384.
  50. Law MA, McMahon WS, Hock KM, et al. Balloon Angioplasty for the Treatment of Left Innominate Vein Obstruction Related Chylothorax after Congenital Heart Surgery. Congenit Heart Dis 2015; 10:E155.